US20030170772A1 - Stabilized tetrazolium-phenazine reagent compositions and methods for using the same - Google Patents
Stabilized tetrazolium-phenazine reagent compositions and methods for using the same Download PDFInfo
- Publication number
- US20030170772A1 US20030170772A1 US10/388,145 US38814503A US2003170772A1 US 20030170772 A1 US20030170772 A1 US 20030170772A1 US 38814503 A US38814503 A US 38814503A US 2003170772 A1 US2003170772 A1 US 2003170772A1
- Authority
- US
- United States
- Prior art keywords
- analyte
- composition
- producing system
- signal producing
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 238000000034 method Methods 0.000 title claims abstract description 32
- 239000012491 analyte Substances 0.000 claims abstract description 91
- 238000012360 testing method Methods 0.000 claims abstract description 66
- 125000003831 tetrazolyl group Chemical group 0.000 claims abstract description 44
- 230000001590 oxidative effect Effects 0.000 claims abstract description 25
- 239000008280 blood Substances 0.000 claims abstract description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims abstract description 19
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 claims abstract description 17
- 238000005259 measurement Methods 0.000 claims abstract description 11
- 108090000854 Oxidoreductases Proteins 0.000 claims abstract description 10
- 102000004316 Oxidoreductases Human genes 0.000 claims abstract description 10
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 10
- 238000001514 detection method Methods 0.000 claims abstract description 9
- 101710088194 Dehydrogenase Proteins 0.000 claims abstract description 6
- 239000000758 substrate Substances 0.000 claims description 18
- -1 phenazine compound Chemical class 0.000 claims description 16
- 239000003381 stabilizer Substances 0.000 claims description 15
- 239000012992 electron transfer agent Substances 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004327 boric acid Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical group [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 210000003722 extracellular fluid Anatomy 0.000 abstract description 8
- 125000001905 inorganic group Chemical group 0.000 abstract description 5
- 239000000523 sample Substances 0.000 description 29
- 229940088598 enzyme Drugs 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 9
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 9
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 9
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 9
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 9
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229910021538 borax Inorganic materials 0.000 description 7
- 239000004328 sodium tetraborate Substances 0.000 description 7
- 235000010339 sodium tetraborate Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- XAZMYOQLNVTRPS-UHFFFAOYSA-L disodium;2-[[4-[2-(1,3-benzothiazol-2-yl)-3-[4-[4-[3-(1,3-benzothiazol-2-yl)-5-[4-[bis(2-sulfonatoethyl)carbamoyl]phenyl]tetrazol-3-ium-2-yl]-3-methoxyphenyl]-2-methoxyphenyl]tetrazol-2-ium-5-yl]benzoyl]-(2-sulfonatoethyl)amino]ethanesulfonate Chemical compound [Na+].[Na+].COC1=CC(C=2C=C(OC)C(=CC=2)N2[N+](=NC(=N2)C=2C=CC(=CC=2)C(=O)N(CCS([O-])(=O)=O)CCS([O-])(=O)=O)C=2SC3=CC=CC=C3N=2)=CC=C1N([N+](=N1)C=2SC3=CC=CC=C3N=2)N=C1C1=CC=C(C(=O)N(CCS([O-])(=O)=O)CCS([O-])(=O)=O)C=C1 XAZMYOQLNVTRPS-UHFFFAOYSA-L 0.000 description 4
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 239000001630 malic acid Substances 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- 229940099690 malic acid Drugs 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 229940107700 pyruvic acid Drugs 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 229940116871 l-lactate Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CXONXVMMINSQBV-NNYOXOHSSA-N (2r,3r,4s,5r)-5-[[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-2-(3-carbamothioylpyridin-1-ium-1-yl)-4-hydroxyoxolan-3-olate Chemical compound NC(=S)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)[O-])=C1 CXONXVMMINSQBV-NNYOXOHSSA-N 0.000 description 2
- VCESGVLABVSDRO-UHFFFAOYSA-L 2-[4-[4-[3,5-bis(4-nitrophenyl)tetrazol-2-ium-2-yl]-3-methoxyphenyl]-2-methoxyphenyl]-3,5-bis(4-nitrophenyl)tetrazol-2-ium;dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC(=CC=2)[N+]([O-])=O)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC(=CC=2)[N+]([O-])=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VCESGVLABVSDRO-UHFFFAOYSA-L 0.000 description 2
- VDJKJPMLWJWQIH-UHFFFAOYSA-M 5-ethylphenazin-5-ium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.C1=CC=C2[N+](CC)=C(C=CC=C3)C3=NC2=C1 VDJKJPMLWJWQIH-UHFFFAOYSA-M 0.000 description 2
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 2
- 102100039702 Alcohol dehydrogenase class-3 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical group N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- JCDBQDNBEQHDHK-BSLNIGMPSA-N [(2r,3s,4r,5r)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2r,3s,4r,5r)-3,4-dihydroxy-5-imidazo[2,1-f]purin-3-yloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C5=NC=CN5C=N4)N=C3)O)O2)O)=C1 JCDBQDNBEQHDHK-BSLNIGMPSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 150000002211 flavins Chemical class 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 108010051015 glutathione-independent formaldehyde dehydrogenase Proteins 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- VTWBTCNQXRKYSS-UHFFFAOYSA-N tc-nbt Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC(=CC=2)C(N)=S)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC(=CC=2)C(N)=S)=NN1C1=CC=C([N+]([O-])=O)C=C1 VTWBTCNQXRKYSS-UHFFFAOYSA-N 0.000 description 2
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- MASUWVVNWALEEM-UHFFFAOYSA-M 1-methoxy-5-methylphenazin-5-ium;methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2N=C3C(OC)=CC=CC3=[N+](C)C2=C1 MASUWVVNWALEEM-UHFFFAOYSA-M 0.000 description 1
- JQQLAEIATYLBQN-UHFFFAOYSA-N 2,3-bis(4-nitrophenyl)-1h-tetrazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1N(C=2C=CC(=CC=2)[N+]([O-])=O)N=CN1 JQQLAEIATYLBQN-UHFFFAOYSA-N 0.000 description 1
- CDJXJFDPAXBVDM-UHFFFAOYSA-N 3,5-diphenyl-2-[4-(2-phenylethenyl)phenyl]-1h-tetrazole Chemical compound N1N(C=2C=CC(C=CC=3C=CC=CC=3)=CC=2)N(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 CDJXJFDPAXBVDM-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- VALWHFRGYCBHIY-UHFFFAOYSA-N 4-(5-methyl-3-phenyl-1h-tetrazol-2-yl)benzoic acid Chemical compound N1C(C)=NN(C=2C=CC=CC=2)N1C1=CC=C(C(O)=O)C=C1 VALWHFRGYCBHIY-UHFFFAOYSA-N 0.000 description 1
- QZHPOWUOLXLXGX-UHFFFAOYSA-N 4-[2-(1,3-benzothiazol-2-yl)-5-[4-(2-sulfoethylcarbamoyl)phenyl]-1h-tetrazol-3-yl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1N1N(C=2SC3=CC=CC=C3N=2)NC(C=2C=CC(=CC=2)C(=O)NCCS(O)(=O)=O)=N1 QZHPOWUOLXLXGX-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 108010015428 Bilirubin oxidase Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 108010000659 Choline oxidase Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- 108010028658 Leucine Dehydrogenase Proteins 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920004894 Triton X-305 Polymers 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical group N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 108010090622 glycerol oxidase Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 108010080601 malate oxidase Proteins 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000002988 phenazines Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QZMUBZJJJKIXKV-UHFFFAOYSA-N pyrroloquinoline quinol Chemical compound N1=C(C(O)=O)C=C(C(O)=O)C2=C(NC(C(=O)O)=C3)C3=C(O)C(O)=C21 QZMUBZJJJKIXKV-UHFFFAOYSA-N 0.000 description 1
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- IRHWMYKYLWNHTL-UHFFFAOYSA-M sodium 2-(N-morpholino)ethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCN1CCOCC1 IRHWMYKYLWNHTL-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- RONADMZTCCPLEF-UHFFFAOYSA-M tetrazolium violet Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C3=CC=CC=C3C=CC=2)=NN1C1=CC=CC=C1 RONADMZTCCPLEF-UHFFFAOYSA-M 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
- G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
Definitions
- the field of this invention is analyte measurement
- Analyte measurement in physiological fluids is of ever increasing importance to today's society.
- Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in diagnosis and management in a variety of disease conditions.
- Analytes of interest include alcohol, formaldehyde, glucose, glutamic acid, glycerol, beta-hydroxybutyrate, L-lactate, leucine, malic acid, pyruvic acid, steroids, etc.
- analyte measurement protocols and devices for both clinical and home use have been developed.
- Patent documents of interest include: U.S. Pat. No. 6,200,773; U.S. Pat. No. 5,902,731; U.S. Pat. No. 4,613,569, U.S. Pat. No. 4,847,196; EP 0 908 453 A1; WO 94/01578 and WO 94/01544.
- Stabilized tetrazolium dye-phenazine reagent compositions that include a tetrazolium dye reagent, e.g., a water soluble tetrazolium salt, and an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents, e.g., an inorganic Group IIIA compound and/or a flavin, are provided.
- a tetrazolium dye reagent e.g., a water soluble tetrazolium salt
- an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents e.g., an inorganic Group IIIA compound and/or a flavin
- the reagent compositions include members of analyte oxidizing signal producing system of which the tetrazolium dye and phenazine reagents are members, which system includes one or more of the following additional components: an analyte oxidizing enzyme, e.g., an analyte dehydrogenase or an analyte oxidase; and an enzyme cofactor.
- an analyte oxidizing enzyme e.g., an analyte dehydrogenase or an analyte oxidase
- an enzyme cofactor e.g., an enzyme cofactor
- test strips that include the subject reagent compositions, as well as systems and kits incorporating the subject test strips.
- the subject reagent compositions, test strips, systems and kits find use in the measurement of a wide variety of analytes in a sample, such as a physiological sample, e.g., blood or a fraction thereof, or ISF (interstitial fluid).
- FIG. 1 provides characterization results of a test strip having a reagent composition with and without borax.
- FIG. 2 provides characterization results of a test strip having a reagent composition with and without FAD.
- FIG. 3 provides characterization results of a test strip having a reagent composition with and without borax and FAD.
- the subject reagent compositions include: (1) a tetrazolium dye component, e.g., a water soluble tetrazolium salt; (2) a phenazine component; and (3) an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents, e.g., an inorganic Group IIIA compound and/or a flavin.
- a tetrazolium dye component e.g., a water soluble tetrazolium salt
- a phenazine component e.g., an inorganic Group IIIA compound and/or a flavin.
- the subject reagent compositions include additional members of an analyte oxidizing signal producing system, such as: an analyte-oxidizing enzyme, e.g., an analyte dehydrogenase or an analyte oxidase; and an enzyme cofactor.
- an analyte-oxidizing enzyme e.g., an analyte dehydrogenase or an analyte oxidase
- an enzyme cofactor e.g., an enzyme cofactor.
- test strips that include the subject reagent compositions, as well as systems and kits incorporating the subject test strips.
- the subject reagent compositions, test strips, systems and kits find use in the detection of a wide variety of analytes in a sample, such as a physiological sample, e.g., blood or a fraction thereof, or ISF (interstitial fluid).
- the subject invention provides stabilized tetrazolium dye compositions and methods for their use, as well as reagent test strips, systems and kits.
- each of these inventive features is discussed in greater detail below.
- the subject invention provides stabilized tetrazolium dye-phenazine reagent compositions, which compositions find use in detecting a wide variety of analytes in a sample.
- the subject tetrazolium dye-phenazine reagent compositions of the present invention are characterized by at least including a tetrazolium dye reagent; a phenazine electron transfer reagent and an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents, e.g., an inorganic Group IIIA compound and/or a flavin.
- the tetrazolium dye reagent is a tetrazolium compound (dye precursor) that, upon acceptance of a transferred hydride, forms a colored formazan product.
- the tetrazolium dye reagent is a water soluble tetrazolium salt that is capable of accepting a hydride to produce a water soluble, colored formazan product.
- Water soluble tetrazolium salts of interest include those described in EP 0 908 453, the disclosure of which is herein incorporated by reference.
- One class of water soluble tetrazolium salts of interest include those described by formula 2 on page 2, lines 35 to 48 of EP 0 908 453.
- Another class of water soluble tetrazolium salts of interest include those described by formula 1 on page 3, lines 10-25 of EP 0 908 453.
- Specific water soluble tetrazolium compounds or salts that are of particular interest include, but are not limited to: 2-(2′benzothiazolyl)-5-styryl-3-(4′-phthalhydrazidyl) tetrazolium (BSPT), 2-benzothiazolyl-(2)-3,5-diphenyl tetrazolium (BTDP), 2,3-di(4-nitrophenyl) tetrazolium (DNP), 2,5-diphenyl-3-(4-styrylphenyl) tetrazolium (DPSP), distyryl nitroblue tetrazolium (DS-NBT), 3,3′-[3,3′-dimethoxy-(1,1′-biphenyl)-4,4′-diyl]-bis[2-(4-nitrophenyl)-5-phenyl(-2H tetrazolium (NBT), 3-(4,5-dimethyl-2-thiazolyl)-2,5-
- the dye compounds is selected from the group of: 2,2′-dibenzothiazolyl-5,5′-bis[4-di(2-sulfoethyl)carbamoylphenyl]-3,3-(3,3-dimethoxy-4,4′-biphenylene)ditetrazolium, disodium salt (WST-5); 2-benzothiazolyl-3-(4-carboxy-2-methoxyphenyl)-5-[4-(2-sulfoethylcarbamoyl)phenyl]-2H-tetrazolium (WST-4) and the like.
- WST-5 is preferred in many embodiments because it readily dissolves in an aqueous medium, which is most compatible with biological samples. Furthermore, the resulting formazan compound exhibits strong spectral absorption at the purple-blue region, thus reducing the need for correcting the background signal from hemoglobin. While the amount of the tetrazolium dye reagent may vary depending on the nature of the reagent composition, e.g., whether it is in dry or wet form, the concentration of the dye reagent in many embodiments ranges from about 1.5 mM to about 50 mM, usually from about 3 mM to about 40 mM and more usually from about 3.5 mM to about 28 mM.
- the subject reagent compositions also include a phenazine electron transfer agent.
- phenazine electron transfer agent is meant a phenazine compound or molecule that can transfer an electron, in the form of a hydride ion, from a reduced enzyme cofactor to the water soluble tetrazolium product.
- Specific phenazine compounds of interest include, but are not limited to: phenazine, phenazine methosulfate (PMS), phenazine ethosulfate, methoxyphenazine methosulfate and safranine.
- the concentration of the phenazine reagent in many embodiments ranges from about 0.01 mM to about 50 mM, usually from about 0.05 mM to about 10 mM and more usually from about 0.1 mM to about 5 mM.
- the subject reagent compositions also include an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents, e.g., an inorganic Group IIIA compound and/or a flavin.
- the subject reagent compositions include an effective amount of a Group IIIA compound.
- the subject compositions include an effective amount of a flavin.
- the subject compositions include effective amounts of both a Group IIIA compound and a flavin.
- effective amount an amount sufficient to stabilize the tetrazolium-phenazine system so that it provides a substantially greater optical density signal after at least about 10 sec than a system that does not include the stabilizing agent(s), as measured using the evaluation protocol reported in the Experimental Section, below.
- An optical density is considered to be substantially greater than a control (where no stabilizing agent is employed) if, at the 10 sec point, it is at least about 2 fold, usually about 2.14 fold greater than the control.
- any convenient Group IIIA compound may be employed which provides for the desired stabilization.
- Representative Group III compounds are those include elements of the Group IIIA column of the periodic table, e.g., B, Al, Ga, In, Tl, where in many embodiments, the Group IIIA compound is a boron or aluminum compound, where of particular interest are inorganic compounds that include these elements, e.g., borates (or boric acid), aluminates, etc., where in many embodiments the compound is a borate, e.g., borax, or boric acid.
- the ratio of Group IIIA stabilizing component to tetrazolium dye in the composition typically ranges from about 50 to about 800, usually from about 100 to about 400.
- the concentration of the Group IIIA stabilizing reagent in the composition ranges from about 0.1 M to about 1.2 M, usually from about 0.2 M to about 1 M.
- any convenient flavin compound may be employed which provides for the desired stabilization.
- Representative flavin compounds are FMN and FAD.
- the ratio of flavin stabilizing component to tetrazolium dye in the composition typically ranges from about 0.02 to about 17, usually from about 0.03 to about 1.
- the concentration of the flavin stabilizing reagent in the composition ranges from about 1 mM to about 25 mM, usually from about 2 mM to about 15 mM.
- the ratio of the amounts of these two agents typically ranges from about 2 to about 800, usually from about 10 to about 400.
- the subject reagent compositions typically further include additional members of an analyte oxidizing signal producing system.
- signal producing system is meant a collection of two or more compounds or molecules which are capable of acting in concert, when combined, to produce a detectable signal that is indicative of the presence of, and often amount of, a particular analyte in a given sample.
- the term signal producing system is used broadly to encompass both a mixture of all of the reagent constituents of the signal producing system as well as a system in which one or more of the reagent constituents are separated from the remainder of the reagent constituents, e.g., as is present in a kit.
- the signal producing system of the subject compositions is an analyte oxidizing signal producing system.
- the analyte oxidizing agent is generally an enzyme that is capable of removing a hydride from the analyte of interest to produce an oxidized form of the analyte.
- Analyte oxidizing enzymes of interest includes analyte oxidases and analyte dehydrogenases.
- Analyte oxidases of interest include, but are not limited to: glucose oxidase (where the analyte is glucose); cholesterol oxidase (where the analyte is cholesterol); alcohol oxidase (where the analyte is alcohol); bilirubin oxidase (where the analyte is bilirubin); choline oxidase (where the analyte is choline); formaldehyde dehydrogenase (where the analyte is formaldehyde); glutamate oxidase (where the analyte is L-glutamic acid); glycerol oxidase (where the analyte is glycerol); galactose oxidase (where the analyte is galactose); L-ascorbate oxidase (where the analyte is ascorbic acid); lactate oxidase (where the analy
- Analyte dehydrogenases of interest include, but are not limited to: alcohol dehydrogenase for alcohol; formaldehyde dehydrogenase for formaldehyde; glucose dehydrogenase for glucose; glucose-6-phosphate dehydrogenase for glucose-6-phosphate; glutamate dehydrogenase for glutamic acid; glycerol dehydrogenase for glycerol; beta-hydroxybutyrate dehydrogenase for beta-hydroxybutyrate; hydroxysteroid dehydrogenase for steroid; L-lactate dehydrogenase for L-lactate; leucine dehydrogenase for leucine; malate dehydrogenase for malic acid, and pyruvate dehydrogenase for pyruvic acid.
- the subject signal producing systems also include an enzyme cofactor that is capable of interacting with the oxidizing agent in a manner such that the analyte of interest is oxidized by the oxidizing agent, which agent concomitantly reduces the enzyme cofactor.
- enzyme cofactors of interest include, but are not limited to: i.e.
- beta-nicotinamide adenine dinucleotide (beta-NAD); beta-nicotinamide adenine dinucleotide phosphate (beta-NADP); thionicotinamide adenine dinucleotide; thionicotinamide adenine dinucleotide phosphate; nicotinamide 1,N6-ethenoadenine dinucleotide; nicotinamide 1,N6-ethenoadenine dinucleotide phosphate; and pyrrolo-quinoline quinone (PQQ); and flavin compounds, FAD, FMN etc.
- Enzyme cofactors of particular interest include: PQQH 2 , NADH or NAD(P)H.
- compositions are present as either wet or dry compositions.
- wet composition is meant a fluid composition, typically an aqueous composition. Such compositions find use in various assay configurations, such as cuvette configurations, which are well known in the art.
- dry compositions is meant a composition that is not fluid, i.e., in dry form, such as a composition that is substantially free of uncombined water. Such compositions are typically found in reagent test strips, as described in greater detail below.
- reagent test strips that include the above described dry reagent compositions and are intended for use in measuring the presence or concentration of an analyte in a sample.
- the invention provides dry strips for assaying for a particular analyte in whole blood, e.g., beta-hydroxybutyrate, glucose, etc.
- the reagent test strip includes a solid support and a dry reagent composition present thereon, where the dry reagent composition is made up of all of the reagent compounds necessary to produce a detectable signal in the presence of the analyte of interest.
- the dry reagent composition present on the subject test strip is one that includes the following members: an analyte oxidizing enzyme, an enzyme cofactor, an electron transfer agent, a water soluble tetrazolium salt, and borate (or boric acid) and/or flavinstabilizing reagents, where each of these constituent members are described in greater detail above.
- the subject test strips include a membrane test pad that is affixed to a solid support.
- the support may be a plastic—e.g., polystyrene, nylon, or polyester—or metallic sheet or any other suitable material known in the art.
- the reagent composition Associated with the test pad, e.g., coated onto the test pad, incorporated into the test pad, etc., is the reagent composition.
- the strip may also be configured in more complex arrangements, e.g., where the test pad is present between the support and a surface layer, where one or more reagents employed in sample processing may be present on the surface layer.
- flow paths or channels may be present on the test strip, as is known in the art.
- the dry reagent composition is associated with, e.g., present on or in, a carrier material or substrate.
- the substrate may be bibulous or non-bibulous.
- bibulous is meant a material that exhibits preferential retention of one or more components as would occur, for example, in materials capable of absorbing or “imbibing” one or more components, as occurs in chromatographic separations.
- Examples of bibulous materials include, but are not limited to: nylon, untreated forms of paper, nitrocellulose and the like which result in chromatographic separation of components contained in liquids, which are passed therethrough.
- the substrate may be non-bibulous.
- Non-bibulous substrates include inert porous matrices, which provide a support for the various members of the signal producing system, described infra, and may have a positive charge. These matrices are generally configured to provide a location for application of a physiological sample, e.g., blood, and detection of the chromogenic product produced by the dye of the signal producing system. As such, the matrix is typically one that is permissive of aqueous fluid flow through it and provides sufficient void space for the chemical reactions of the signal producing system to take place.
- porous matrices have been developed for use in various analyte measurement assays, which matrices may differ in terms of materials, pore sizes, dimensions and the like, where representative matrices include those described in U.S. Pat. Nos. 55,932,431; 5,874,099; 5,871,767; 5,869,077; 5,866,322; 5,834,001; 5,800,829; 5,800,828; 5,798,113; 5,670,381; 5,663,054; 5,459,080; 5,459,078; 5,441,894 and 5,212,061; the disclosures of which are herein incorporated by reference.
- the dimensions and porosity of the test strip may vary greatly, where the matrix may or may not have a porosity gradient, e.g., with larger pores near or at the sample application region and smaller pores at the detection region.
- the matrix is configured as a membrane test pad and is affixed to a solid support, where the support may be a plastic (e.g., polystyrene, nylon or polyester) or metallic sheet or any other suitable material known in the art.
- plastic e.g., polystyrene, nylon or polyester
- metallic sheet any other suitable material known in the art.
- test strip configurations are provided in U.S. Pat. Nos. 6,200,733 and 5,902,731, the disclosures of which are herein incorporated by reference.
- the subject test strips may be fabricated employing any convenient protocol.
- One convenient protocol is to contact at least the test pad portion of the strip with an aqueous composition that includes all of the members of the reagent composition that are to be associated with the test pad in the final reagent test strip.
- the test pad may be immersed in the aqueous composition, maintained therein for a sufficient period of time and then dried, whereby the test pad of the reagent test strip, which has associated therewith the reagent composition, is produced.
- the aqueous composition will include the various members of the reagent composition to be associated with the test pad of the reagent test strip, where the various members are present in amounts sufficient to provide for the desired amounts in the reagent composition that is produced on the test pad.
- the concentration of electron transfer agent present in this aqueous composition typically ranges from about 10 to 50,000, usually from about 50 to 10,000 and more usually from about 100 to 5,000 ⁇ M.
- the concentration of the proteinaceous electron transfer agent present in the aqueous composition typically ranges from about 10 to 10,000, usually from about 50 to 5,000 and more usually from about 100 to 3,000 U/ml.
- the concentration of tetrazolium dye, e.g., tetrazolium salt, present in the aqueous composition ranges from about 3 mM to 36 mM, usually from about 6 mM to 24 mM.
- the enzyme cofactor ranges in concentration from about 1.5 mM to 28 mM, usually from about 3.5 mM to 14 mM.
- the analyte oxidizing agent enzyme ranges in concentration from about 100 U to 5000 U, and usually from about 200 U to 4000 U/ml when present.
- the above described signal producing systems, reagent compositions and test strips find use in methods of detecting the presence of, and often the amount of, i.e., the concentration of, an analyte in a sample.
- a variety of different analytes may be detected using the subject methods, where representative analytes include those described above, e.g., alcohol, formaldehyde, glucose, glutamic acid, glycerol, beta-hydroxybutyrate, L-lactate, leucine, malic acid, pyruvic acid, steroids, etc.
- the subject methods may be used to determine the presence, and often concentration, of an analyte in a variety of different physiological samples, such as urine, tears, saliva, and the like, they are particularly suited for use in determining the concentration of an analyte in blood or blood fractions, e.g., blood derived samples, and more particularly in whole blood, ISF (interstitial fluid).
- blood or blood fractions e.g., blood derived samples, and more particularly in whole blood, ISF (interstitial fluid).
- the sample and the signal producing system are combined into a reaction mixture, the reaction is allowed to proceed for a sufficient period to time to generate a signal indicative of the presence of (and often amount of) analyte in the sample, and the resultant signal is detected and related to the presence of (and often amount of) analyte in the sample.
- the above steps may take place in a suitable volume containment means, e.g., cuvette, where the reagent composition is a fluid composition. In many embodiments, the above steps take place on a reagent test strip as described supra.
- a feature of the subject methods is that the detectable signal is made up of a non-washable spot that forms on the surface of the substrate of the strip.
- the non-washable spot is made up of water soluble formazan product which is tightly bound to the substrate surface such that it cannot be readily removed from the surface under standard washing conditions.
- standard washing conditions is meant the conditions experienced by substrate surface in analyte detection assays where unbound component has to be removed from the surface.
- An example of standard washing conditions are those employed by those of skill in the art in array based nucleic acid hybridization assays, where non-hybridized nucleic acids are removed from the surface of an array following a hybridization step. Such conditions are well known to those of skill in the art.
- a feature of the subject methods is the production of a non-washable spot on the surface of the positively charged substrate, where the non-washable spot is made up of the water soluble formazan product.
- the first step is to apply a quantity of the physiological sample to the test strip, where the test strip is described supra.
- the amount of physiological sample, e.g., blood that is applied to the test strip may vary, but generally ranges from about 2 ⁇ L to 40 ⁇ L, usually from about 5 ⁇ L to 20 ⁇ L.
- the blood sample size that is applied to the test strip may be relatively small, ranging in size from about 21 ⁇ L to 40 ⁇ L, usually from about 5 ⁇ L to 20 ⁇ L.
- blood samples of a variety of different hematocrits may be assayed with the subject methods, where the hematocrit may range from about 20% to 65%, usually from about 25% to 60%.
- the sample is allowed to react with the members of the signal producing system to produce a detectable product, i.e., the non-washable spot, that is present in an amount proportional to the initial amount of the analyte of interest present in the sample.
- the amount of detectable product i.e., signal produced by the signal producing system in the form of the non-washable spot, is then determined and related to the amount of analyte in the initial sample.
- automated instruments that perform the above mentioned detection and relation steps are employed. The above described reaction, detection and relating steps, as well as instruments for performing the same, are further described in U.S. Pat. Nos.
- kits for use in practicing the subject methods at least include a signal producing system as described above, where the signal producing system components may be combined into a single reagent composition or separated, e.g., present in separate containers. In certain embodiments, the signal producing system will be present in the kits in the form of a reagent test strip, as described supra.
- the subject kits may further include a means for obtaining a physiological sample. For example, where the physiological sample is blood, the subject kits may further include a means for obtaining a blood sample, such as a lance for sticking a finger, a lance actuation means, and the like.
- the subject kits may include a control solution or standard, e.g.
- kits also include an automated instrument, as described above, for detecting the amount of product produced on the strip following sample application and relating the detected product to the amount of analyte in the sample.
- the subject kits typically further include instructions for using the components of the kit to practice the subject methods with the subject devices.
- the instructions for practicing the subject methods are generally recorded on a suitable recording medium.
- the instructions may be printed on a substrate, such as paper or plastic, etc.
- the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc.
- the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc.
- the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided.
- An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
- a 0.8 ⁇ m nylon membrane obtained from Pall Corporation (East Hills, N.Y.) was dipped into the reagent of Table 1, until saturated. The excess reagent was scraped off gently with a glass rod. The resulting membrane was hung to dry in a 56° C. oven for 10 minutes. (Porex (0.6 mm thick) was soaked in the nitrite solution of Table 2 and then hung to dry in a 100° C. oven for ten hours. Finally, the membrane was laminated between a polyester stock (0.4 mm Melenex® polyester from ICI America, Wilmington, Del.) and the nitrite-impregnated Porex.)
- Gantrez 6% (Gantrez AN-139 (Poly Methylvinylether-alt-Maleic 2-4 gm Anhydride, MW 1080000, Cat # 41632-0, Aldrich Chemicals, Milwaukee, WI USA) Make 6% Gantrez in water, heat to 95° C. for less than 45 min. to get Gantrez 6% which is ready for use). Adjust pH to 5.5-7 by adding 50% NaOH Triton X-305 (BASF Corporation, Mount Olive, NJ, USA) 0.5 to 2 gm. Mannitol (MW 182, Sigma, St.
- FIG. 1 With and without Borax, after stressed at 56° C. for 1 week, tested with blood of 60%HCT and 370 mg/dL Glucose.
- FIG. 2 With and without FAD, after stressed at 56° C. for 1 week, tested with blood of 60%HCT and 370 mg/dL Glucose.
- FIG. 3 with and without Borax and FAD, after stressed at 56° C. for 1 week, tested with blood of 60%HCT and 370 mg/dL Glucose.
- the subject invention provides for improvement over previous tetrazolium dye-phenazine reagent compositions, in that it provides for a convenient way to stabilize the dye-electron transfer agent component of the system so that light and/or heat exposure does not adversely effect the dye.
- the subject invention represents a significant contribution to the art.
Abstract
Stabilized tetrazolium dye-phenazine reagent compositions and methods for their use in the measurement of an analyte in a sample are provided. The subject reagent compositions include: (1) a tetrazolium dye component, e.g., a water soluble tetrazolium salt; (2) a phenazine component; and (3) an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents, e.g., an inorganic Group IIIA compound and/or a flavin. In many embodiments, the subject reagent compositions include additional members of an analyte oxidizing signal producing system, such as: an analyte oxidizing enzyme, e.g., an analyte dehydrogenase or an analyte oxidase; and an enzyme cofactor. Also provided are test strips that include the subject reagent compositions, as well as systems and kits incorporating the subject test strips. The subject reagent compositions, test strips, systems and kits find use in the detection of a wide variety of analytes in a sample, such as a physiological sample, e.g., blood or a fraction thereof, or ISF (interstitial fluid).
Description
- 1. Field of the Invention
- The field of this invention is analyte measurement
- 2. Background of the Invention
- Analyte measurement in physiological fluids, e.g., blood or blood-derived products, is of ever increasing importance to today's society. Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in diagnosis and management in a variety of disease conditions. Analytes of interest include alcohol, formaldehyde, glucose, glutamic acid, glycerol, beta-hydroxybutyrate, L-lactate, leucine, malic acid, pyruvic acid, steroids, etc. In response to this growing importance of analyte measurement, a variety of analyte measurement protocols and devices for both clinical and home use have been developed.
- Many of the protocols and devices that have been developed to date employ a signal producing system to identify the presence of the analyte of interest in a physiological sample, such as blood.
- While a variety of such signal producing systems have been developed to date for use in the measurement of a wide variety of different analytes, there continues to be a need for the further development of such systems.
- Relevant Literature
- Patent documents of interest include: U.S. Pat. No. 6,200,773; U.S. Pat. No. 5,902,731; U.S. Pat. No. 4,613,569, U.S. Pat. No. 4,847,196;
EP 0 908 453 A1; WO 94/01578 and WO 94/01544. - Stabilized tetrazolium dye-phenazine reagent compositions that include a tetrazolium dye reagent, e.g., a water soluble tetrazolium salt, and an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents, e.g., an inorganic Group IIIA compound and/or a flavin, are provided. In many embodiments, the reagent compositions include members of analyte oxidizing signal producing system of which the tetrazolium dye and phenazine reagents are members, which system includes one or more of the following additional components: an analyte oxidizing enzyme, e.g., an analyte dehydrogenase or an analyte oxidase; and an enzyme cofactor. Also provided are test strips that include the subject reagent compositions, as well as systems and kits incorporating the subject test strips. The subject reagent compositions, test strips, systems and kits find use in the measurement of a wide variety of analytes in a sample, such as a physiological sample, e.g., blood or a fraction thereof, or ISF (interstitial fluid).
- FIG. 1 provides characterization results of a test strip having a reagent composition with and without borax.
- FIG. 2 provides characterization results of a test strip having a reagent composition with and without FAD.
- FIG. 3 provides characterization results of a test strip having a reagent composition with and without borax and FAD.
- Stabilized tetrazolium dye-phenazine reagent compositions and methods for their use in the measurement of an analyte in a sample are provided. The subject reagent compositions include: (1) a tetrazolium dye component, e.g., a water soluble tetrazolium salt; (2) a phenazine component; and (3) an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents, e.g., an inorganic Group IIIA compound and/or a flavin. In many embodiments, the subject reagent compositions include additional members of an analyte oxidizing signal producing system, such as: an analyte-oxidizing enzyme, e.g., an analyte dehydrogenase or an analyte oxidase; and an enzyme cofactor. Also provided are test strips that include the subject reagent compositions, as well as systems and kits incorporating the subject test strips. The subject reagent compositions, test strips, systems and kits find use in the detection of a wide variety of analytes in a sample, such as a physiological sample, e.g., blood or a fraction thereof, or ISF (interstitial fluid).
- Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.
- In this specification and the appended claims, the singular forms “a,” “an” and “the” include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.
- All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies, which are described in the publications, which might be used in connection with the presently described invention.
- As summarized above, the subject invention provides stabilized tetrazolium dye compositions and methods for their use, as well as reagent test strips, systems and kits. In further describing the invention, each of these inventive features is discussed in greater detail below.
- Reagent Compositions
- As summarized above, the subject invention provides stabilized tetrazolium dye-phenazine reagent compositions, which compositions find use in detecting a wide variety of analytes in a sample. The subject tetrazolium dye-phenazine reagent compositions of the present invention are characterized by at least including a tetrazolium dye reagent; a phenazine electron transfer reagent and an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents, e.g., an inorganic Group IIIA compound and/or a flavin.
- The tetrazolium dye reagent is a tetrazolium compound (dye precursor) that, upon acceptance of a transferred hydride, forms a colored formazan product. In many embodiments, the tetrazolium dye reagent is a water soluble tetrazolium salt that is capable of accepting a hydride to produce a water soluble, colored formazan product. Water soluble tetrazolium salts of interest include those described in
EP 0 908 453, the disclosure of which is herein incorporated by reference. One class of water soluble tetrazolium salts of interest include those described byformula 2 onpage 2, lines 35 to 48 ofEP 0 908 453. Another class of water soluble tetrazolium salts of interest include those described byformula 1 onpage 3, lines 10-25 ofEP 0 908 453. - Specific water soluble tetrazolium compounds or salts that are of particular interest include, but are not limited to: 2-(2′benzothiazolyl)-5-styryl-3-(4′-phthalhydrazidyl) tetrazolium (BSPT), 2-benzothiazolyl-(2)-3,5-diphenyl tetrazolium (BTDP), 2,3-di(4-nitrophenyl) tetrazolium (DNP), 2,5-diphenyl-3-(4-styrylphenyl) tetrazolium (DPSP), distyryl nitroblue tetrazolium (DS-NBT), 3,3′-[3,3′-dimethoxy-(1,1′-biphenyl)-4,4′-diyl]-bis[2-(4-nitrophenyl)-5-phenyl(-2H tetrazolium (NBT), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium (MTT), 2-phenyl-3-(4-carboxyphenyl)-5-methyl tetrazolium (PCPM), tetrazolium blue (TB), thiocarbamyl nitroblue tetrazolium (TCNBT), tetranitroblue tetrazolium (TNBT), tetrazolium violet, (TV), 2-benzothiazothiazolyl-3-(4-carboxy-2-methoxyphenyl)-5-[4-(2-sulfoethylcar bamoyl)phenyl]-2H-tetrazolium (WST-4), and 2,2′-dibenzothiazolyl-5,5′-bis[4-di(2-sulfoethyl)carbamoylphenyl]-3,3′-(3, 3′-dimethoxy-4,4′-biphenylene)ditetrazolium, disodium salt (WST-5). In certain embodiments, the dye compounds is selected from the group of: 2,2′-dibenzothiazolyl-5,5′-bis[4-di(2-sulfoethyl)carbamoylphenyl]-3,3-(3,3-dimethoxy-4,4′-biphenylene)ditetrazolium, disodium salt (WST-5); 2-benzothiazolyl-3-(4-carboxy-2-methoxyphenyl)-5-[4-(2-sulfoethylcarbamoyl)phenyl]-2H-tetrazolium (WST-4) and the like. WST-5 is preferred in many embodiments because it readily dissolves in an aqueous medium, which is most compatible with biological samples. Furthermore, the resulting formazan compound exhibits strong spectral absorption at the purple-blue region, thus reducing the need for correcting the background signal from hemoglobin. While the amount of the tetrazolium dye reagent may vary depending on the nature of the reagent composition, e.g., whether it is in dry or wet form, the concentration of the dye reagent in many embodiments ranges from about 1.5 mM to about 50 mM, usually from about 3 mM to about 40 mM and more usually from about 3.5 mM to about 28 mM.
- The subject reagent compositions also include a phenazine electron transfer agent. By phenazine electron transfer agent is meant a phenazine compound or molecule that can transfer an electron, in the form of a hydride ion, from a reduced enzyme cofactor to the water soluble tetrazolium product. Specific phenazine compounds of interest include, but are not limited to: phenazine, phenazine methosulfate (PMS), phenazine ethosulfate, methoxyphenazine methosulfate and safranine. While the amount of the phenazine electron transfer reagent may vary depending on the nature of the reagent composition, e.g., whether it is in dry or wet form, the concentration of the phenazine reagent in many embodiments ranges from about 0.01 mM to about 50 mM, usually from about 0.05 mM to about 10 mM and more usually from about 0.1 mM to about 5 mM.
- In addition to the tetrazolium dye and phenazine components described above, the subject reagent compositions also include an effective amount of one or more tetrazolium dye-phenazine stabilizing reagents, e.g., an inorganic Group IIIA compound and/or a flavin. As such, in certain embodiments, the subject reagent compositions include an effective amount of a Group IIIA compound. In other embodiments, the subject compositions include an effective amount of a flavin. In yet other embodiments, the subject compositions include effective amounts of both a Group IIIA compound and a flavin. By effective amount is meant an amount sufficient to stabilize the tetrazolium-phenazine system so that it provides a substantially greater optical density signal after at least about 10 sec than a system that does not include the stabilizing agent(s), as measured using the evaluation protocol reported in the Experimental Section, below. An optical density is considered to be substantially greater than a control (where no stabilizing agent is employed) if, at the 10 sec point, it is at least about 2 fold, usually about 2.14 fold greater than the control.
- Any convenient Group IIIA compound may be employed which provides for the desired stabilization. Representative Group III compounds are those include elements of the Group IIIA column of the periodic table, e.g., B, Al, Ga, In, Tl, where in many embodiments, the Group IIIA compound is a boron or aluminum compound, where of particular interest are inorganic compounds that include these elements, e.g., borates (or boric acid), aluminates, etc., where in many embodiments the compound is a borate, e.g., borax, or boric acid. The ratio of Group IIIA stabilizing component to tetrazolium dye in the composition typically ranges from about 50 to about 800, usually from about 100 to about 400. As such, in many embodiments, the concentration of the Group IIIA stabilizing reagent in the composition ranges from about 0.1 M to about 1.2 M, usually from about 0.2 M to about 1 M.
- Any convenient flavin compound may be employed which provides for the desired stabilization. Representative flavin compounds are FMN and FAD. The ratio of flavin stabilizing component to tetrazolium dye in the composition typically ranges from about 0.02 to about 17, usually from about 0.03 to about 1. As such, in many embodiments, the concentration of the flavin stabilizing reagent in the composition ranges from about 1 mM to about 25 mM, usually from about 2 mM to about 15 mM.
- Where both a Group IIIA and flavin stabilizing agent are present in the composition, the ratio of the amounts of these two agents typically ranges from about 2 to about 800, usually from about 10 to about 400.
- The presence of the stabilizing agent(s) described above stabilizes the tetrazolium dye-phenazine system, as described above, with respect to heat (56° C.) exposure of at least about one week.
- As mentioned above, the subject reagent compositions typically further include additional members of an analyte oxidizing signal producing system. By signal producing system is meant a collection of two or more compounds or molecules which are capable of acting in concert, when combined, to produce a detectable signal that is indicative of the presence of, and often amount of, a particular analyte in a given sample. The term signal producing system is used broadly to encompass both a mixture of all of the reagent constituents of the signal producing system as well as a system in which one or more of the reagent constituents are separated from the remainder of the reagent constituents, e.g., as is present in a kit.
- As mentioned above, the signal producing system of the subject compositions is an analyte oxidizing signal producing system. The analyte oxidizing agent is generally an enzyme that is capable of removing a hydride from the analyte of interest to produce an oxidized form of the analyte. Analyte oxidizing enzymes of interest includes analyte oxidases and analyte dehydrogenases. Analyte oxidases of interest include, but are not limited to: glucose oxidase (where the analyte is glucose); cholesterol oxidase (where the analyte is cholesterol); alcohol oxidase (where the analyte is alcohol); bilirubin oxidase (where the analyte is bilirubin); choline oxidase (where the analyte is choline); formaldehyde dehydrogenase (where the analyte is formaldehyde); glutamate oxidase (where the analyte is L-glutamic acid); glycerol oxidase (where the analyte is glycerol); galactose oxidase (where the analyte is galactose); L-ascorbate oxidase (where the analyte is ascorbic acid); lactate oxidase (where the analyte is lactic acid); leucine oxidase (where the analyte is leucine); malate oxidase (where the analyte is malic acid); pyruvate oxidase (where the analyte is pyruvic acid); urate oxidase (where the analyte is uric acid); and the like.
- Analyte dehydrogenases of interest include, but are not limited to: alcohol dehydrogenase for alcohol; formaldehyde dehydrogenase for formaldehyde; glucose dehydrogenase for glucose; glucose-6-phosphate dehydrogenase for glucose-6-phosphate; glutamate dehydrogenase for glutamic acid; glycerol dehydrogenase for glycerol; beta-hydroxybutyrate dehydrogenase for beta-hydroxybutyrate; hydroxysteroid dehydrogenase for steroid; L-lactate dehydrogenase for L-lactate; leucine dehydrogenase for leucine; malate dehydrogenase for malic acid, and pyruvate dehydrogenase for pyruvic acid.
- In many embodiments, the subject signal producing systems also include an enzyme cofactor that is capable of interacting with the oxidizing agent in a manner such that the analyte of interest is oxidized by the oxidizing agent, which agent concomitantly reduces the enzyme cofactor. Enzyme cofactors of interest include, but are not limited to: i.e. beta-nicotinamide adenine dinucleotide (beta-NAD); beta-nicotinamide adenine dinucleotide phosphate (beta-NADP); thionicotinamide adenine dinucleotide; thionicotinamide adenine dinucleotide phosphate;
nicotinamide 1,N6-ethenoadenine dinucleotide;nicotinamide 1,N6-ethenoadenine dinucleotide phosphate; and pyrrolo-quinoline quinone (PQQ); and flavin compounds, FAD, FMN etc. Enzyme cofactors of particular interest that may be included in the subject signal producing systems include: PQQH2, NADH or NAD(P)H. - As indicated above, the subject compositions are present as either wet or dry compositions. By wet composition is meant a fluid composition, typically an aqueous composition. Such compositions find use in various assay configurations, such as cuvette configurations, which are well known in the art. By dry compositions is meant a composition that is not fluid, i.e., in dry form, such as a composition that is substantially free of uncombined water. Such compositions are typically found in reagent test strips, as described in greater detail below.
- Reagent Test Strips
- Of particular interest in many embodiments of the subject invention are reagent test strips that include the above described dry reagent compositions and are intended for use in measuring the presence or concentration of an analyte in a sample. In particular, the invention provides dry strips for assaying for a particular analyte in whole blood, e.g., beta-hydroxybutyrate, glucose, etc. In the broadest sense, the reagent test strip includes a solid support and a dry reagent composition present thereon, where the dry reagent composition is made up of all of the reagent compounds necessary to produce a detectable signal in the presence of the analyte of interest. In most embodiments of the subject invention, the dry reagent composition present on the subject test strip is one that includes the following members: an analyte oxidizing enzyme, an enzyme cofactor, an electron transfer agent, a water soluble tetrazolium salt, and borate (or boric acid) and/or flavinstabilizing reagents, where each of these constituent members are described in greater detail above.
- In many embodiments, the subject test strips include a membrane test pad that is affixed to a solid support. The support may be a plastic—e.g., polystyrene, nylon, or polyester—or metallic sheet or any other suitable material known in the art. Associated with the test pad, e.g., coated onto the test pad, incorporated into the test pad, etc., is the reagent composition. The strip may also be configured in more complex arrangements, e.g., where the test pad is present between the support and a surface layer, where one or more reagents employed in sample processing may be present on the surface layer. In addition, flow paths or channels may be present on the test strip, as is known in the art. Of interest in many embodiments is the test strip configurations disclosed in U.S. Pat. No. 5,902,731, the disclosure of which is herein incorporated by reference.
- In the subject test strips, the dry reagent composition is associated with, e.g., present on or in, a carrier material or substrate. The substrate may be bibulous or non-bibulous. By bibulous is meant a material that exhibits preferential retention of one or more components as would occur, for example, in materials capable of absorbing or “imbibing” one or more components, as occurs in chromatographic separations. Examples of bibulous materials include, but are not limited to: nylon, untreated forms of paper, nitrocellulose and the like which result in chromatographic separation of components contained in liquids, which are passed therethrough.
- Alternatively, the substrate may be non-bibulous. Non-bibulous substrates include inert porous matrices, which provide a support for the various members of the signal producing system, described infra, and may have a positive charge. These matrices are generally configured to provide a location for application of a physiological sample, e.g., blood, and detection of the chromogenic product produced by the dye of the signal producing system. As such, the matrix is typically one that is permissive of aqueous fluid flow through it and provides sufficient void space for the chemical reactions of the signal producing system to take place. A number of different porous matrices have been developed for use in various analyte measurement assays, which matrices may differ in terms of materials, pore sizes, dimensions and the like, where representative matrices include those described in U.S. Pat. Nos. 55,932,431; 5,874,099; 5,871,767; 5,869,077; 5,866,322; 5,834,001; 5,800,829; 5,800,828; 5,798,113; 5,670,381; 5,663,054; 5,459,080; 5,459,078; 5,441,894 and 5,212,061; the disclosures of which are herein incorporated by reference. The dimensions and porosity of the test strip may vary greatly, where the matrix may or may not have a porosity gradient, e.g., with larger pores near or at the sample application region and smaller pores at the detection region. In many embodiments, the matrix is configured as a membrane test pad and is affixed to a solid support, where the support may be a plastic (e.g., polystyrene, nylon or polyester) or metallic sheet or any other suitable material known in the art. Of interest in many embodiments are the test strip configurations disclosed in U.S. Pat. Nos. 5,972,294; 5,968,836; 5,968,760; 5,902,731; 5,846,486; 5,843,692; 5,843,691; 5,789,255; 5,780,304; 5,753,452; 5,753,429; 5,736,103; 5,719,034; 5,714,123; 383,550; 381,591; 5,620,863; 5,605,837; 5,563,042; 5,526,120; 5,515,170; 367,109; 5,453,360; 5,426,032; 5,418,142; 5,306,623; 5,304,468; 5,179,005; 5,059,394; 5,049,487; 4,935,346; 4,900,666 and 4,734,360, the disclosures of which are herein incorporated by reference.
- Examples of suitable representative test strip configurations are provided in U.S. Pat. Nos. 6,200,733 and 5,902,731, the disclosures of which are herein incorporated by reference.
- The subject test strips may be fabricated employing any convenient protocol. One convenient protocol is to contact at least the test pad portion of the strip with an aqueous composition that includes all of the members of the reagent composition that are to be associated with the test pad in the final reagent test strip. Conveniently, the test pad may be immersed in the aqueous composition, maintained therein for a sufficient period of time and then dried, whereby the test pad of the reagent test strip, which has associated therewith the reagent composition, is produced. As stated above, the aqueous composition will include the various members of the reagent composition to be associated with the test pad of the reagent test strip, where the various members are present in amounts sufficient to provide for the desired amounts in the reagent composition that is produced on the test pad. As such, where the electron transfer agent is non-proteinaceous, the concentration of electron transfer agent present in this aqueous composition typically ranges from about 10 to 50,000, usually from about 50 to 10,000 and more usually from about 100 to 5,000 μM. In other embodiment which containing both non-proteinaceous and proteinaceous eletron transfer agents, the concentration of the proteinaceous electron transfer agent present in the aqueous composition typically ranges from about 10 to 10,000, usually from about 50 to 5,000 and more usually from about 100 to 3,000 U/ml. The concentration of tetrazolium dye, e.g., tetrazolium salt, present in the aqueous composition ranges from about 3 mM to 36 mM, usually from about 6 mM to 24 mM. When present, the enzyme cofactor ranges in concentration from about 1.5 mM to 28 mM, usually from about 3.5 mM to 14 mM. Similarly, the analyte oxidizing agent enzyme ranges in concentration from about 100 U to 5000 U, and usually from about 200 U to 4000 U/ml when present. The amount of Group IIIA stabilizing agent, e.g., borax (or boric aid), when present, typically ranges from about 0.1 M to about 1 M, usually from about 0.2 M to about 0.6 M. The amount of flavin stabilizing agent, e.g., FAD, FMN, when present, typically ranges from about 1 mM to about 25 mM, usually from about 2 mM to about 15 mM. See the experimental section, infra, for a more detailed description of a representative method for preparing the subject reagent test strips.
- Methods of Analyte Measurement
- The above described signal producing systems, reagent compositions and test strips find use in methods of detecting the presence of, and often the amount of, i.e., the concentration of, an analyte in a sample. A variety of different analytes may be detected using the subject methods, where representative analytes include those described above, e.g., alcohol, formaldehyde, glucose, glutamic acid, glycerol, beta-hydroxybutyrate, L-lactate, leucine, malic acid, pyruvic acid, steroids, etc. While in principle, the subject methods may be used to determine the presence, and often concentration, of an analyte in a variety of different physiological samples, such as urine, tears, saliva, and the like, they are particularly suited for use in determining the concentration of an analyte in blood or blood fractions, e.g., blood derived samples, and more particularly in whole blood, ISF (interstitial fluid).
- In the subject methods, the sample and the signal producing system are combined into a reaction mixture, the reaction is allowed to proceed for a sufficient period to time to generate a signal indicative of the presence of (and often amount of) analyte in the sample, and the resultant signal is detected and related to the presence of (and often amount of) analyte in the sample. The above steps may take place in a suitable volume containment means, e.g., cuvette, where the reagent composition is a fluid composition. In many embodiments, the above steps take place on a reagent test strip as described supra.
- In certain embodiments, a feature of the subject methods is that the detectable signal is made up of a non-washable spot that forms on the surface of the substrate of the strip. The non-washable spot is made up of water soluble formazan product which is tightly bound to the substrate surface such that it cannot be readily removed from the surface under standard washing conditions. By standard washing conditions is meant the conditions experienced by substrate surface in analyte detection assays where unbound component has to be removed from the surface. An example of standard washing conditions are those employed by those of skill in the art in array based nucleic acid hybridization assays, where non-hybridized nucleic acids are removed from the surface of an array following a hybridization step. Such conditions are well known to those of skill in the art. As such, a feature of the subject methods is the production of a non-washable spot on the surface of the positively charged substrate, where the non-washable spot is made up of the water soluble formazan product.
- In practicing many embodiments of the subject methods, the first step is to apply a quantity of the physiological sample to the test strip, where the test strip is described supra. The amount of physiological sample, e.g., blood that is applied to the test strip may vary, but generally ranges from about 2 μL to 40 μL, usually from about 5 μL to 20 μL. Because of the nature of the subject test strip, the blood sample size that is applied to the test strip may be relatively small, ranging in size from about 21 μL to 40 μL, usually from about 5 μL to 20 μL. Where blood is the physiological sample, blood samples of a variety of different hematocrits may be assayed with the subject methods, where the hematocrit may range from about 20% to 65%, usually from about 25% to 60%.
- Following application of the sample to the test strip, the sample is allowed to react with the members of the signal producing system to produce a detectable product, i.e., the non-washable spot, that is present in an amount proportional to the initial amount of the analyte of interest present in the sample. The amount of detectable product, i.e., signal produced by the signal producing system in the form of the non-washable spot, is then determined and related to the amount of analyte in the initial sample. In certain embodiments, automated instruments that perform the above mentioned detection and relation steps are employed. The above described reaction, detection and relating steps, as well as instruments for performing the same, are further described in U.S. Pat. Nos. 4,734,360; 4,900,666; 4,935,346; 5,059,394; 5,304,468; 5,306,623; 5,418,142; 5,426,032; 5,515,170; 5,526,120; 5,563,042; 5,620,863; 5,753,429; 5,573,452; 5,780,304; 5,789,255; 5,843,691; 5,846,486; 5,902,731; 5,968,836 and 5,972,294; the disclosures of which are herein incorporated by reference. In the relation step, the derived analyte concentration takes into account the constant contribution of competing reactions to the observed signal, e.g., by calibrating the instrument accordingly. KITS
- Also provided by the subject invention are kits for use in practicing the subject methods. The kits of the subject invention at least include a signal producing system as described above, where the signal producing system components may be combined into a single reagent composition or separated, e.g., present in separate containers. In certain embodiments, the signal producing system will be present in the kits in the form of a reagent test strip, as described supra. The subject kits may further include a means for obtaining a physiological sample. For example, where the physiological sample is blood, the subject kits may further include a means for obtaining a blood sample, such as a lance for sticking a finger, a lance actuation means, and the like. In addition, the subject kits may include a control solution or standard, e.g. an analyte control solution that contains a standardized concentration of analyte. In certain embodiments, the kits also include an automated instrument, as described above, for detecting the amount of product produced on the strip following sample application and relating the detected product to the amount of analyte in the sample.
- In addition to above mentioned components, the subject kits typically further include instructions for using the components of the kit to practice the subject methods with the subject devices. The instructions for practicing the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
- The following examples are offered by way of illustration and not by way of limitation.
- A 0.8 μm nylon membrane obtained from Pall Corporation (East Hills, N.Y.) was dipped into the reagent of Table 1, until saturated. The excess reagent was scraped off gently with a glass rod. The resulting membrane was hung to dry in a 56° C. oven for 10 minutes. (Porex (0.6 mm thick) was soaked in the nitrite solution of Table 2 and then hung to dry in a 100° C. oven for ten hours. Finally, the membrane was laminated between a polyester stock (0.4 mm Melenex® polyester from ICI America, Wilmington, Del.) and the nitrite-impregnated Porex.)
- Table 2 and Porex are not Needed if Table 1 Contains NaNO2.
TABLE 1 Reagent for a Glucose Test Pad Components Quantity Water 100 ml (2-[-Morpholino]ethanesulfonic acid) sodium salt MES (MW 217.2, 0.8-2.2 gm Sigma, St. Louis, MO, USA) Adjust pH to 5-7 by adding 6 M HCl) Borax (MW 381.4, Sigma, St. Louis, Mo, USA 2-4 gm Gantrez 6% (Gantrez AN-139 (Poly Methylvinylether-alt-Maleic 2-4 gm Anhydride, MW 1080000, Cat # 41632-0, Aldrich Chemicals, Milwaukee, WI USA) Make 6% Gantrez in water, heat to 95° C. for less than 45 min. to get Gantrez 6% which is ready for use). Adjust pH to 5.5-7 by adding 50% NaOH Triton X-305 (BASF Corporation, Mount Olive, NJ, USA) 0.5 to 2 gm. Mannitol (MW 182, Sigma, St. Louis, MO, USA) 1-10 gm Adjust pH to 5.5-7 by adding 50% NaOH Sodium Nitrite (MW 69, Aldrich Chemicals, Milwaukee, WI USA) 1-5 gm.* Phenazine Ethosulfate (PES, MW 334.4, Sigma, St. Louis, MO, USA 100-1000 mg WST-5 (MW 1331.37, Dojindo Laboratory, Japan) 0.8-4 gm Glucose Oxidase (GO, TOYOBO) 100-1000 KU Flavin Adenine Dinucleotide (FAD) 0.2-1 gm - * If NaNO2 is in Table 1, Table 2 is not needed. If NaNO2 is not in Table 1, Table 2 is needed.
TABLE 2 Nitrite Reagent Components Quantity 10 mM Phosphate Buffer Saline, pH 7.4, (P-3813, Sigma, 70 ml St. Louis, MO, USA) Ethanol 30 ml Sodium Nitrite (MW69, Aldrich Chemicals, Milwaukee, 5 gm WI, USA) Polyvinylpyrrodine (MW 40,000, Sigma, St. Louis, 200 mg MO, USA) - FIG. 1. With and without Borax, after stressed at 56° C. for 1 week, tested with blood of 60%HCT and 370 mg/dL Glucose.
- FIG. 2. With and without FAD, after stressed at 56° C. for 1 week, tested with blood of 60%HCT and 370 mg/dL Glucose.
- FIG. 3 with and without Borax and FAD, after stressed at 56° C. for 1 week, tested with blood of 60%HCT and 370 mg/dL Glucose.
- It is evident from the above results and discussion that the subject invention provides for improvement over previous tetrazolium dye-phenazine reagent compositions, in that it provides for a convenient way to stabilize the dye-electron transfer agent component of the system so that light and/or heat exposure does not adversely effect the dye. As such, the subject invention represents a significant contribution to the art.
- All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
- Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Claims (32)
1. A reagent composition comprising:
A tetrazolium dye;
A phenazine electron transfer agent; and
An effective amount of a Group IIIA compound and/or a flavin stabilizing agent.
2. The composition according to claim 1 , wherein said flavin stabilizing agent is FAD.
3. The composition according to claim 1 , wherein said Group IIIA stabilizing agent is a borate or boric acid.
4. The composition according to claim 1 , wherein said reagent composition comprises an analyte oxidizing signal producing system.
5. The composition according to claim 4 , wherein said analyte oxidizing signal producing system comprises an analyte oxidase.
6. The composition according to claim 4 , wherein said analyte oxidizing signal producing system comprises an analyte dehydrogenase.
7. The composition according to claim 4 , wherein said phenazine compound is PES.
8. The composition according to claim 4 , wherein said analyte oxidizing signal producing system further comprises an enzyme cofactor.
9. The composition according to claim 1 , wherein said composition is a fluid composition.
10. The composition according to claim 1 , wherein said composition is a dry composition.
11. A reagent test strip comprising:
A substrate; and
An analyte oxidizing signal producing system present on said substrate, wherein said analyte oxidizing signal producing system includes: (a) a water soluble tetrazolium salt; (b) a phenazine electron transfer agent; and (c) an effective amount of Group IIIA compound and/or flavin stabilizing agent.
12. The test strip according to claim 11 , wherein said wherein said flavin stablizing agent is FAD.
13. The test strip according to claim 11 , wherein said Group IIIA stabilizing agent is a borate or boric acid.
14. The test strip according to claim 11 , wherein said analyte oxidizing signal producing system comprises an analyte oxidase.
15. The test strip according to claim 14 , wherein said phenazine is PES.
16. The test strip according to claim 14 , wherein said analyte oxidizing signal-producing system further comprises an enzyme cofactor.
17. The test strip according to claim 10 , wherein said analyte oxidizing signal producing system is a glucose oxidizing signal producing system.
18. An analyte detection or measurement system comprising:
(A) A reagent test strip comprising:
(i) A substrate; and
(ii) An analyte oxidizing signal producing system present on said substrate, wherein said analyte oxidizing signal producing system includes: (a) a water soluble tetrazolium salt; (b) a phenazine electron transfer agent; and (c) an effective amount of Group IIIA compound and/or flavin stabilizing agent; and
(B) An automated instrument.
19. A method for detecting the presence or determining the concentration of an analyte in a sample, said method comprising:
(A) Applying said physiological sample to a reagent test strip comprising:
(i) A substrate; and
(ii) An analyte oxidizing signal producing system present on said substrate, wherein said analyte oxidizing signal producing system includes: (a) a water soluble tetrazolium salt; (b) a phenazine electron transfer agent; and (c) an effective amount of Group IIIA compound and/or flavin stabilizing agent;
(B) Detecting said spot; and
(C) Relating said detected spot to the presence or concentration of said analyte in said physiological sample.
20. The method according to claim 19 , wherein said signal producing system further comprises an analyte oxidase.
21. The method according to claim 20 , wherein said phenazine is PES.
22. The method according to claim 19 , wherein said sample is whole blood or a derivative thereof.
23. The method according to claim 19 , wherein said detecting and relating steps are carried out by an automated instrument.
24. A kit for use in determining the concentration of an analyte in a physiological sample, said kit comprising:
(A) A reagent test strip comprising:
(i) A substrate; and
(ii) An analyte oxidizing signal producing system present on said substrate, wherein said analyte oxidizing signal producing system includes: (a) a water soluble tetrazolium salt; (b) a phenazine electron transfer agent; and (c) an effective amount of Group IIIA compound and/or flavin stabilizing agent; and
(B) At least one of:
(i) A means for obtaining said physiological sample and
(ii) An analyte standard.
25. The kit according to claim 24 , wherein said means for obtaining said physiological sample is a lance.
26. The kit according to claim 24 , wherein said analyte standard comprises a standardized concentration of a known reagent.
27. The kit according to claim 24 , wherein said kit comprises a means for obtaining said physiological sample and an analyte standard.
28. A method for stabilizing a tetrazolium dye-phenazine reagent composition, said method comprising:
Including in said reagent composition an effective amount of a Group IIIA compound and/or a flavin stabilizing agent.
29. The method according to claim 28 , wherein said Group IIIA compound is a borate or boric acid.
30. The method according to claim 28 , wherein said flavin is FAD.
31. The method according to claim 28 , wherein said reagent composition is a dry composition.
32. The method according to claim 28 , wherein said reagent composition is a wet composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/388,145 US20030170772A1 (en) | 2001-11-20 | 2003-03-12 | Stabilized tetrazolium-phenazine reagent compositions and methods for using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/988,494 US6939685B2 (en) | 2001-11-20 | 2001-11-20 | Stabilized tetrazolium phenazine reagent compositions and methods for using the same |
US10/388,145 US20030170772A1 (en) | 2001-11-20 | 2003-03-12 | Stabilized tetrazolium-phenazine reagent compositions and methods for using the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/988,494 Division US6939685B2 (en) | 2001-11-20 | 2001-11-20 | Stabilized tetrazolium phenazine reagent compositions and methods for using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030170772A1 true US20030170772A1 (en) | 2003-09-11 |
Family
ID=25534172
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/988,494 Expired - Lifetime US6939685B2 (en) | 2001-11-20 | 2001-11-20 | Stabilized tetrazolium phenazine reagent compositions and methods for using the same |
US10/388,145 Abandoned US20030170772A1 (en) | 2001-11-20 | 2003-03-12 | Stabilized tetrazolium-phenazine reagent compositions and methods for using the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/988,494 Expired - Lifetime US6939685B2 (en) | 2001-11-20 | 2001-11-20 | Stabilized tetrazolium phenazine reagent compositions and methods for using the same |
Country Status (16)
Country | Link |
---|---|
US (2) | US6939685B2 (en) |
EP (1) | EP1312921A1 (en) |
JP (1) | JP2004000129A (en) |
KR (1) | KR20030041809A (en) |
CN (1) | CN1432653A (en) |
AR (1) | AR037544A1 (en) |
BR (1) | BR0204761A (en) |
CA (1) | CA2412198A1 (en) |
HK (1) | HK1052969A1 (en) |
IL (1) | IL152918A0 (en) |
MX (1) | MXPA02011478A (en) |
NO (1) | NO20025489L (en) |
PL (1) | PL357203A1 (en) |
RU (1) | RU2002131153A (en) |
SG (1) | SG115506A1 (en) |
TW (1) | TW200303864A (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US7316700B2 (en) | 2001-06-12 | 2008-01-08 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
WO2002100460A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Electric lancet actuator |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
AU2002348683A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US6586199B2 (en) * | 2001-11-20 | 2003-07-01 | Lifescan, Inc. | Stabilized tetrazolium reagent compositions and methods for using the same |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
ES2347248T3 (en) | 2003-05-30 | 2010-10-27 | Pelikan Technologies Inc. | PROCEDURE AND APPLIANCE FOR FLUID INJECTION. |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
EP1765194A4 (en) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Method and apparatus for a fluid sampling device |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
AU2008272818A1 (en) * | 2007-07-02 | 2009-01-08 | Yu, Ming Dr | Methods, composition, targets for combinational cancer treatments |
US8008037B2 (en) | 2008-03-27 | 2011-08-30 | Roche Diagnostics Operations, Inc. | Matrix composition with alkylphenazine quaternary salt and a nitrosoaniline |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4613569A (en) * | 1980-12-23 | 1986-09-23 | Boehringer Mannheim Gmbh | Stabilized composition of tetrazolium salts |
US4724204A (en) * | 1982-08-23 | 1988-02-09 | Medi-Pharma Vertriebsgesellschaft Mbh | Diagnostic device for the detection of increased dehydrogenase or oxidase and the use thereof |
US5902731A (en) * | 1998-09-28 | 1999-05-11 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2147466C3 (en) | 1971-09-23 | 1980-06-26 | Boehringer Mannheim Gmbh, 6800 Mannheim | 5- (4-N-trimethyl-ammonium-phenyl) tetrazolium salts |
JPS6070861A (en) * | 1983-09-27 | 1985-04-22 | Fujitsu Ltd | Data transmission and reception device |
US5126247A (en) | 1988-02-26 | 1992-06-30 | Enzymatics, Inc. | Method, system and devices for the assay and detection of biochemical molecules |
WO1994001544A1 (en) | 1992-07-02 | 1994-01-20 | Boehringer Mannheim Corporation | A reagent stabilized by bivalent metal salts |
DE69327242T2 (en) | 1992-07-02 | 2000-05-25 | Roche Diagnostics Corp | STABILIZATION OF TETRAZOLIUM SALTS IN A REAGENT |
JP2757348B2 (en) | 1996-04-18 | 1998-05-25 | 株式会社同仁化学研究所 | New water-soluble tetrazolium salt compound |
US6656697B1 (en) | 1998-09-28 | 2003-12-02 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds |
-
2001
- 2001-11-20 US US09/988,494 patent/US6939685B2/en not_active Expired - Lifetime
-
2002
- 2002-11-14 SG SG200206874A patent/SG115506A1/en unknown
- 2002-11-15 NO NO20025489A patent/NO20025489L/en not_active Application Discontinuation
- 2002-11-18 AR ARP020104420A patent/AR037544A1/en unknown
- 2002-11-18 IL IL15291802A patent/IL152918A0/en unknown
- 2002-11-19 MX MXPA02011478A patent/MXPA02011478A/en unknown
- 2002-11-19 KR KR1020020071962A patent/KR20030041809A/en not_active Application Discontinuation
- 2002-11-19 EP EP02257964A patent/EP1312921A1/en not_active Withdrawn
- 2002-11-19 RU RU2002131153/15A patent/RU2002131153A/en not_active Application Discontinuation
- 2002-11-19 TW TW091133666A patent/TW200303864A/en unknown
- 2002-11-19 JP JP2002335506A patent/JP2004000129A/en active Pending
- 2002-11-19 CN CN02139980A patent/CN1432653A/en active Pending
- 2002-11-19 CA CA002412198A patent/CA2412198A1/en not_active Abandoned
- 2002-11-19 PL PL02357203A patent/PL357203A1/en not_active Application Discontinuation
- 2002-11-21 BR BR0204761-6A patent/BR0204761A/en not_active Application Discontinuation
-
2003
- 2003-03-12 US US10/388,145 patent/US20030170772A1/en not_active Abandoned
- 2003-07-15 HK HK03105121.8A patent/HK1052969A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4613569A (en) * | 1980-12-23 | 1986-09-23 | Boehringer Mannheim Gmbh | Stabilized composition of tetrazolium salts |
US4847196A (en) * | 1980-12-23 | 1989-07-11 | Boehringer Mannheim Gmbh | Stabilized composition of tetrazolium salts |
US4724204A (en) * | 1982-08-23 | 1988-02-09 | Medi-Pharma Vertriebsgesellschaft Mbh | Diagnostic device for the detection of increased dehydrogenase or oxidase and the use thereof |
US5902731A (en) * | 1998-09-28 | 1999-05-11 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds |
US6200773B1 (en) * | 1998-09-28 | 2001-03-13 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds |
Also Published As
Publication number | Publication date |
---|---|
RU2002131153A (en) | 2004-07-10 |
NO20025489L (en) | 2003-05-21 |
PL357203A1 (en) | 2003-06-02 |
CA2412198A1 (en) | 2003-05-20 |
US6939685B2 (en) | 2005-09-06 |
JP2004000129A (en) | 2004-01-08 |
HK1052969A1 (en) | 2003-10-03 |
KR20030041809A (en) | 2003-05-27 |
US20030096389A1 (en) | 2003-05-22 |
CN1432653A (en) | 2003-07-30 |
NO20025489D0 (en) | 2002-11-15 |
AR037544A1 (en) | 2004-11-17 |
EP1312921A1 (en) | 2003-05-21 |
TW200303864A (en) | 2003-09-16 |
IL152918A0 (en) | 2003-06-24 |
MXPA02011478A (en) | 2004-12-13 |
BR0204761A (en) | 2003-09-16 |
SG115506A1 (en) | 2005-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6939685B2 (en) | Stabilized tetrazolium phenazine reagent compositions and methods for using the same | |
US6586199B2 (en) | Stabilized tetrazolium reagent compositions and methods for using the same | |
US6420128B1 (en) | Test strips for detecting the presence of a reduced cofactor in a sample and method for using the same | |
AU763065B2 (en) | Diagnostics based on tetrazolium compounds | |
AU782774B2 (en) | Diagnostics based on tetrazolium compounds | |
CA2404421A1 (en) | Reagent systems for detecting the presence of a reduced cofactor in a sample and methods for using the same | |
AU2001288935A2 (en) | Test-strips with positively charged membranes for tetrazolium based assays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |